Még nem toboroz
A Study of LY4336619 in Adult Participants With Advanced Solid Tumors
NCT07928258· 1. fázis· Eli Lilly and Company· Forrás
Toboroz
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT07707895· 1/2. fázis· Boehringer Ingelheim· Forrás
Toboroz
A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)
NCT07843940· 1/2. fázis· Boehringer Ingelheim· Forrás
Toboroz
A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.
NCT07734116· 1/2. fázis· Ono Pharmaceutical Co., Ltd.· Forrás
Toboroz
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
NCT07566052· 3. fázis· Astellas Pharma Global Development, Inc.· Forrás
Toboroz
AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer
NCT07617337· 1. fázis· Chugai Pharmaceutical· Forrás
Toboroz
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
NCT07549412· 3. fázis· EMD Serono Research & Development Institute, Inc.· Forrás
Toboroz
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
NCT07225270· 3. fázis· Genmab· Forrás
Toboroz
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
NCT07221149· 2/3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849· 3. fázis· Incyte Corporation· Forrás
Toboroz
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
NCT07227298· 1/2. fázis· Pfizer· Forrás
Toboroz
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT07219212· 1. fázis· Johnson & Johnson Enterprise Innovation Inc.· Forrás
Toboroz
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357· 2/3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
NCT07128199· 3. fázis· Taiho Oncology, Inc.· Forrás
Toboroz
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800· 3. fázis· Pfizer· Forrás
Toboroz
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
NCT07226999· 2/3. fázis· Pfizer· Forrás
Fut, nem toboroz
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07214779· 3. fázis· Incyte Corporation· Forrás
Toboroz
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146· 3. fázis· Zai Lab (Shanghai) Co., Ltd.· Forrás
Toboroz
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
NCT07166094· 3. fázis· Genmab· Forrás
Toboroz
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07023627· 2. fázis· Incyte Corporation· Forrás
Toboroz
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
NCT07173751· 3. fázis· BioNTech SE· Forrás
Toboroz
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
NCT06989437· 2/3. fázis· Pfizer· Forrás
Toboroz
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280· 3. fázis· Pfizer· Forrás
Toboroz
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
NCT07005154· 2. fázis· Astellas Pharma Global Development, Inc.· Forrás
Fut, nem toboroz
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07005128· 3. fázis· Amgen· Forrás
Toboroz
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109· 3. fázis· Nuvalent Inc.· Forrás
Toboroz
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531· 3. fázis· Astellas Pharma Global Development, Inc.· Forrás
Fut, nem toboroz
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
NCT06806852· 1. fázis· Boehringer Ingelheim· Forrás
Toboroz
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784· 3. fázis· Revolution Medicines, Inc.· Forrás
Toboroz
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
NCT06644781· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
NCT06914128· 1/2. fázis· Bayer· Forrás
Toboroz
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007· 3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
NCT06745323· 2. fázis· Amgen· Forrás
Fut, nem toboroz
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
NCT06619236· 3. fázis· Genmab· Forrás
Toboroz
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
NCT06712316· 2/3. fázis· BioNTech SE· Forrás
Fut, nem toboroz
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
NCT06593522· 2. fázis· Amgen· Forrás
Toboroz
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185· 1. fázis· Eli Lilly and Company· Forrás
Toboroz
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386· 3. fázis· Bristol-Myers Squibb· Forrás
Fut, nem toboroz
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
NCT06561685· 1. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
NCT06333951· 1. fázis· Amgen· Forrás
Fut, nem toboroz
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441· 3. fázis· Gilead Sciences· Forrás
Showing 50 of 119.